This developer of antibody-based therapeutics has seen a mixed track record when it comes to estimate revisions of 2 increases and 2 decreases in the last 30 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
XOMA currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the biomedical industry may consider stocks like Affymetrix Inc. (AFFX), Biogen Idec Inc. (BIIB) and AMAG Pharmaceuticals, Inc. (AMAG). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment